NKGen Biotech

About:

NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.

Website: https://nkgenbiotech.com/

Twitter/X: nkgenbiotech

Top Investors: Gaingels

Description:

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability to infinitely expand natural killer cells while significantly enhancing cytotoxicity.

Total Funding Amount:

$16M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Santa Ana, California, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)nkgenbiotech.com

Founders:

Sangwoo Park

Number of Employees:

51-100

Last Funding Date:

2024-04-11

IPO Status:

Public

Industries:

© 2025 bioDAO.ai